Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 12/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 12/20 | 0.53 |
| ▸ | KCNE1 | P15382 | 7/20 | 0.53 |
| ▸ | KCNQ1 | P51787 | 7/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31378805 | 1.00 | KCNQ3 (0.53) | KCNQ3KCNQ2KCNE1KCNQ1NAMPT | |
| SCHEMBL27743755 | 0.84 | GAA (0.46) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL376258 | 0.84 | NAMPT (0.56) | KCNQ3KCNQ2NAMPTMAPKAPK2CYP17A1 | |
| SCHEMBL6609814 | 0.84 | NAMPT (0.52) | NAMPTMAPKAPK2CYP17A1 | |
| SCHEMBL30208803 | 0.84 | NAMPT (0.56) | KCNQ3KCNQ2NAMPTMAPKAPK2CYP17A1 | |
| SCHEMBL22110342 | 0.83 | MAPKAPK2 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1NAMPT | |
| SCHEMBL4942948 | 0.83 | NAMPT (0.51) | NAMPTMAPKAPK2CYP17A1 | |
| SCHEMBL4910310 | 0.83 | NAMPT (0.51) | NAMPTMAPKAPK2CYP17A1ATR | |
| SCHEMBL31190971 | 0.83 | NAMPT (0.51) | NAMPTMAPKAPK2CYP17A1 | |
| SCHEMBL31363779 | 0.83 | NAMPT (0.51) | NAMPTMAPKAPK2CYP17A1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492199-B2 | Pyridopyrimidines as histamine H4-receptor inhibitors | FAES FARMA, S.A. (ES) | 2025-12-09 | — | — | US | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20240360147-A1 | Process for Synthesizing Naphthyridine Derivatives and Intermediates Thereof | AMGEN INC. | 2024-10-31 | — | — | US | disclosed |
| US-12071421-B2 | Process for the synthesis of substituted chloromethyl dialkylphosphates | HELSINN HEALTHCARE SA (CH) | 2024-08-27 | — | — | US | disclosed |
| EP-4396170-A1 | PROCESS FOR SYNTHESIZING NAPHTHYRIDINE DERIVATIVES AND INTERMEDIATES THEREOF | Amgen Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12006302-B2 | Tau PET imaging ligands | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-11 | — | — | US | disclosed |
| US-11980609-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4337641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240002375-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE | REMIX THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| US-6169091-B1 | TREATMENT OF PSORIASIS, FIBROSIS, ATHEROSCLEROSIS, RESTENOSIS, AUTO-IMMUNE DISEASE, ALLERGY, ASTHMA | GLAXO WELLCOME INC. | 2001-01-02 | — | — | US | disclosed |
| US-6140499-A | 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICAL COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0929533-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | Du Pont Pharmaceuticals Company (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5874430-A | COMPOUNDS AS PROTEASE, REVERSE TRANSCRIPTASE INHIBITORS FOR DIAGNOSIS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998014436-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-09 | — | — | WO | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| CN-1139383-A | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | WARNER LAMBERT CO (US) | 1997-01-01 | — | — | CN | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360147-A1 | Process for Synthesizing Naphthyridine Derivatives and Intermediates Thereof | NME1, NPM1, NME2 | KCNQ3 2838/4885KCNQ2 2394/4885KCNE1 2222/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | KCNQ3 3123/4885KCNQ2 2613/4885KCNE1 2574/4885 |
| US-20240002375-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE | POLRMT, HNRNPA1, SNRPA | KCNQ3 4532/4885KCNQ2 4556/4885KCNE1 4478/4885 |
| US-12006302-B2 | Tau PET imaging ligands | MAPT, PSEN1, APP | KCNQ3 1578/4885KCNQ2 1948/4885KCNE1 3314/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | KCNQ3 4358/4885KCNQ2 4117/4885KCNE1 3006/4885 |
| US-11980609-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | KCNQ3 2966/4885KCNQ2 3313/4885KCNE1 3177/4885 |
| US-12071421-B2 | Process for the synthesis of substituted chloromethyl dialkylphosphates | BDKRB1, BDKRB2, TK1 | KCNQ3 858/4885KCNQ2 862/4885KCNE1 385/4885 |
| US-12492199-B2 | Pyridopyrimidines as histamine H4-receptor inhibitors | HRH4, HRH2, HRH3 | KCNQ3 397/4885KCNQ2 239/4885KCNE1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.